Clinical trials: Smoking Behavior
Smoking Cessation, Harm Reduction
Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on…
- Trial name
- NCT06554873
- Testing
- Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking, Smoking Behaviors
CSD210903: A Study to Determine Subject Puffing Patterns of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Ambulatory Setting
This is a multi-center, open-label, parallel-cohort-study to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) combustible cigarette (CC) and/or a UB Heated Tobacco…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05307822
- Testing
- Non-combusted cigarette variant 42001401, Non-combusted cigarette variant 42001399, Non-combusted cigarette variant 40007386
- Where
- 7 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation, Tobacco Use Cessation
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.
- Trial name
- NCT00218413
- Testing
- NicVAX
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Nabi Biopharmaceuticals
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation.
- Trial name
- NCT00150254
- Testing
- CP-526,555 (varenicline)
- Where
- 13 sites in United States
- Volunteers
- 625 people
- Sponsor
- Pfizer
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
- Trial name
- RENEW-Smk-1 (NCT07223840)
- Testing
- Brenipatide
- Where
- 29 sites in United States, China and 1 more
- Volunteers
- 222 people
- Sponsor
- Eli Lilly and Company
Tobacco Dependence
Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum
Single-dose pharmacokinetics with two new oral nicotine replacement products and Nicorette® gum.
- Trial name
- NCT01152723
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- McNeil AB
Malformations
Varenicline Pregnancy Cohort Study
A prospective population-based cohort study to examine whether varenicline use during pregnancy is associated with an increased risk of major congenital malformations in infants above that associated with smoking during pregnancy.
- Trial name
- NCT01290445
- Testing
- varenicline, cigarette smoke from maternal smoking, Non-Exposure
- Volunteers
- 885,185 people
- Sponsor
- Pfizer
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Depressive Disorder, Pregnancy
Bupropion and Specific Cardiovascular Malformations
The study is an extension of earlier work based on a retrospective epidemiologic study of infants born to women who were exposed to bupropion in their estimated first trimester of pregnancy using data from a large US health plan…
- Conditions
- Depressive Disorder, Pregnancy, Smoking Cessation
- Trial name
- NCT01165255
- Testing
- 3. Exposure to other antidepressants during the first trimester comparison cohort, 2. Exposure to bupropion outside the first trimester comparison cohort, 1. Exposure to bupropion during the first trimester
- Volunteers
- 7,005 people
- Sponsor
- GlaxoSmithKline
Vaping, E-Cig Use
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
- Trial name
- ORCA-V1 (NCT05431387)
- Testing
- cytisinicline, Behavioral support
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Achieve Life Sciences
Smoking, Cigarette
Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.
This study is a randomized, open-label, 2-way, 2-period, single-dose crossover clinical study to compare the pharmacokinetic characteristics and the safety between zeropix tablet 1 mg and champix® tablet 1 mg in healthy adult…
- Trial name
- NCT03362008
- Testing
- Zeropix, Champix®
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Electronic Cigarette Use, Cigarette Use, Electronic
Evaluating Selected Constituents in the Exhaled Breath Samples
An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, Mint, Mango, Menthol) Users and Conventional…
- Conditions
- Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
- Trial name
- NCT04143256
- Testing
- JUUL ENDS 5% Virginia Tobacco, JUUL 3% Virginia Tobacco ENDS, JUUL 5% Mint ENDS
- Where
- 3 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Smoking Cessation
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
- Trial name
- NCT00483002
- Testing
- varenicline
- Volunteers
- 3,719 people
- Sponsor
- Pfizer
Smoking Cessation, Pharmacokinetics
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"
A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers
- Trial name
- NCT04631874
- Testing
- CDFF0318, Champix
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CTC Bio, Inc.
Smoking
Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial
The purpose of the "Weigh2Quit" study was to test in a randomized trial, a "weight concerns" intervention designed to reduce weight concerns that might impact cessation, increase physical activity and adherence to tobacco…
- Trial name
- OKRCT (NCT01162577)
- Testing
- Weight Concerns
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Smoking, Smoking Behaviors
CSD190601: A Study to Determine Subject Puffing Patterns of Electronic Nicotine Delivery Systems in an Ambulatory Setting
This study will be a single-center, controlled, open-label, parallel two-study-group investigation to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) Electronic…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT04308434
- Testing
- CSD190601-11, CSD190601-12, CSD190601-13
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Cigarette Smoking
Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes
This is a randomized, open-label, forced-switch, parallel, proof-of-concept study to assess exposure to biomarkers of tobacco exposure following short-term ad lib use of three blu e-cigarette products.
- Trial name
- NCT02385227
- Testing
- Exclusive blu™ e-cigarette A1, Exclusive blu™ e-cigarette A2, Exclusive blu™ e-cigarette A3
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Lorillard Tobacco Company
Smoking Cessation
Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers.
- Trial name
- NCT03432273
- Testing
- Nicotine lozenge
- Where
- South Africa
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to…
- Trial name
- NCT05994703
- Testing
- d-cycloserine, Juul e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC